Maxcyte (MXCT) Accumulated Depreciation (2020 - 2026)

Maxcyte (MXCT) has 7 years of Accumulated Depreciation data on file, last reported at $18.3 million in Q1 2026.

• Accumulated Depreciation for Q1 2026 came in at $18.3 million, up 16.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.3 million (up 16.97% YoY), and the FY2025 annual result was $17.3 million, up 27.02% from the prior year.
• Accumulated Depreciation rose to $18.3 million in Q1 2026 per MXCT's latest filing, from $17.3 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $18.3 million in Q1 2026 and troughed at $4.8 million in Q1 2022.
• A 5-year average of $11.2 million and a median of $11.4 million in 2024 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2023 and 2026: Accumulated Depreciation soared 65.6% in 2023, then increased 16.97% in 2026.
• A 5-year view of Accumulated Depreciation shows it stood at $6.3 million in 2022, then soared by 63.92% to $10.3 million in 2023, then surged by 32.14% to $13.6 million in 2024, then climbed by 27.02% to $17.3 million in 2025, then gained by 5.83% to $18.3 million in 2026.
• Business Quant data shows MXCT's Accumulated Depreciation at $18.3 million in Q1 2026, $17.3 million in Q4 2025, and $17.0 million in Q3 2025.